NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Phase 2

Withdrawn

Conditions: Advanced Malignant Solid Neoplasm
Advanced Lymphoma
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Biological: Relatlimab

First Posted Date: 2024-05-06

Last Posted Date: 2024-05-06

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT06400264

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Refractory Multiple Myeloma
Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Copanlisib
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06400238

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Refractory Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Refractory Multiple Myeloma
Refractory Lymphoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-05-06

Last Posted Date: 2025-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06400251

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase 1

Not yet recruiting

Conditions: Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent High Grade Endometrioid Adenocarcinoma
Recurrent Ovarian Seromucinous Carcinoma
Recurrent Ovarian Undifferentiated Carcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Platinum-Refractory Fallopian Tube Carcinoma
Platinum-Refractory Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinosarcoma
Platinum-Refractory Ovarian Carcinoma
Recurrent Fallopian Tube Undifferentiated Carcinoma

Interventions: Biological: Bevacizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Drug: Tolinapant

First Posted Date: 2024-05-01

Last Posted Date: 2025-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 127

Registration Number: NCT06393751

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Sapanisertib

First Posted Date: 2024-04-30

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT06390865

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Refractory Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Radionuclide Imaging
Drug: Sunitinib

First Posted Date: 2024-04-30

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT06390826

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Advanced Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma
Refractory Lymphoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Larotrectinib
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-04-30

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06390852

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Palbociclib

First Posted Date: 2024-04-30

Last Posted Date: 2025-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT06390839

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma
Advanced Lymphoma

Interventions: Drug: Afatinib
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Radionuclide Imaging

First Posted Date: 2024-04-26

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT06385483

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Multiple Myeloma
Advanced Lymphoma
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Sapanisertib

First Posted Date: 2024-04-26

Last Posted Date: 2025-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06385496

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Home Terms & Conditions Privacy Policy